Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful PostSurgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2 Breast Cancer
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group...